BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30211724)

  • 1. Comparison of Clinical Characteristics and Outcomes in Relapsed Versus De Novo Metastatic Non-Small Cell Lung Cancer.
    Gibson AJW; Li H; D'Silva A; Tudor RA; Elegbede AA; Otsuka S; Bebb DG; Cheung WY
    Am J Clin Oncol; 2019 Jan; 42(1):75-81. PubMed ID: 30211724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival Implications of De Novo Versus Recurrent Metastatic Non-Small Cell Lung Cancer.
    Moore S; Leung B; Wu J; Ho C
    Am J Clin Oncol; 2019 Mar; 42(3):292-297. PubMed ID: 30608237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer.
    Gibson AJW; Li H; D'Silva A; Tudor RA; Elegbede AA; Otsuka SM; Bebb DG; Cheung WY
    Med Oncol; 2018 Aug; 35(9):117. PubMed ID: 30073425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
    den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
    Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 7th and 8th editions of the UICC/AJCC TNM staging for non-small cell lung cancer in a non-metastatic North American cohort undergoing primary radiation treatment.
    Koul R; Rathod S; Dubey A; Bashir B; Chowdhury A
    Lung Cancer; 2018 Sep; 123():116-120. PubMed ID: 30089581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival differences among women with de novo stage IV and relapsed breast cancer.
    Dawood S; Broglio K; Ensor J; Hortobagyi GN; Giordano SH
    Ann Oncol; 2010 Nov; 21(11):2169-2174. PubMed ID: 20427349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study.
    Hendriks LE; Derks JL; Postmus PE; Damhuis RA; Houben RM; Troost EG; Hochstenbag MM; Smit EF; Dingemans AM
    Eur J Cancer; 2015 Nov; 51(17):2534-44. PubMed ID: 26323530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non-Small Cell Lung Cancer.
    Su CC; Wu JT; Choi E; Myall NJ; Neal JW; Kurian AW; Stehr H; Wood D; Henry SM; Backhus LM; Leung AN; Wakelee HA; Han SS
    JAMA Netw Open; 2023 Sep; 6(9):e2335813. PubMed ID: 37751203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
    Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
    Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer.
    Darling GE; Li F; Patsios D; Massey C; Wallis AG; Coate L; Keshavjee S; Pierre A; De Perrot M; Yasufuku K; Cypel M; Waddell T
    Eur J Cardiothorac Surg; 2015 Nov; 48(5):684-90; discussion 690. PubMed ID: 25567960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
    Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
    Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
    Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
    Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.
    Baine MJ; Verma V; Schonewolf CA; Lin C; Simone CB
    Lung Cancer; 2018 Apr; 118():20-26. PubMed ID: 29571997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Asian ethnicity on outcome in metastatic EGFR-mutant non-small cell lung cancer.
    Gibson AJW; D'Silva A; Elegbede AA; Tudor RA; Dean ML; Bebb DG; Hao D
    Asia Pac J Clin Oncol; 2019 Dec; 15(6):343-352. PubMed ID: 31486229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer.
    Ito H; Matsuo Y; Ohtsu S; Nishimura T; Terada Y; Sakamoto T; Mizowaki T
    Int J Clin Oncol; 2020 Feb; 25(2):274-281. PubMed ID: 31667664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
    Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
    BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of outcomes between women with de novo stage IV and relapsed breast cancer.
    Kitagawa D; Horiguchi S; Yamashita T; Kuroi K; Shimizu K
    J Nippon Med Sch; 2014; 81(3):139-47. PubMed ID: 24998960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Population-based Study of Treatment Patterns and Survival of Patients With De Novo Stage IV Non-Small Cell Lung Cancer.
    Batra A; Yusuf D; Hurry M; Walton RN; Devost N; Farrer C; Cheung WY
    Am J Clin Oncol; 2021 Oct; 44(10):512-518. PubMed ID: 34380947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
    Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
    Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].
    Li Y; Sun BS; Zhang ZF; Zhang LM; Wang CL
    Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(24):1682-6. PubMed ID: 21914316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.